Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22859150 | 0.93 | BRD4 (0.75) | BRD4BRDT | |
| SCHEMBL26655730 | 0.92 | BRD4 (0.72) | BRD4BRDT | |
| SCHEMBL26655728 | 0.85 | BRD4 (0.63) | BRD4BRDT | |
| SCHEMBL22859369 | 0.84 | BRD4 (0.71) | BRD4BRDT | |
| SCHEMBL26655726 | 0.84 | BRD4 (0.71) | BRD4BRDT | |
| SCHEMBL22859376 | 0.83 | BRD4 (1.00) | BRD4BRDT | |
| SCHEMBL29533657 | 0.83 | BRD4 (1.00) | BRD4BRDT | |
| SCHEMBL22859447 | 0.83 | BRD4 (0.84) | BRD4BRDT | |
| SCHEMBL26655741 | 0.83 | BRD4 (0.78) | BRD4BRDT | |
| SCHEMBL22859276 | 0.82 | BRD4 (0.77) | BRD4BRDT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339964-A1 | HETEROCYCLIC COMPOUNDS AS BET INHIBITORS | NUVATION BIO INC (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230339964-A1 | HETEROCYCLIC COMPOUNDS AS BET INHIBITORS | NUVATION BIO INC (US) | 2023-10-26 | — | — | US | disclosed |
| US-11584756-B2 | Heterocyclic compounds as BET inhibitors | NUVATION BIO INC. (US) | 2023-02-21 | — | — | US | disclosed |
| US-20210002293-A1 | HETEROCYCLIC COMPOUNDS AS BET INHIBITORS | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2021-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11584756-B2 | Heterocyclic compounds as BET inhibitors | BET1, BRD4, BRD3 | BRD4 2/4885BRDT 4/4885 |
| US-20230339964-A1 | HETEROCYCLIC COMPOUNDS AS BET INHIBITORS | BET1, BRD4, BRD3 | BRD4 2/4885BRDT 4/4885 |
| US-20210002293-A1 | HETEROCYCLIC COMPOUNDS AS BET INHIBITORS | BET1, BRD4, BRD3 | BRD4 2/4885BRDT 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.